Ajanta Pharma has received approval from the US health regulator for generic Omeprazole and sodium bicarbonate powder for oral suspension used for the treatment of stomach and esophagus problems such as ulcers and acid reflux.
The company has received approval from the United States Food and Drug Administration (USFDA) for the same and will soon be launching the product, Ajanta Pharma said in a BSE filing.
The launch will be in two strengths, 20 mg/1680 mg and 40 mg /1680 mg powder sachets, it added.
The product is a generic version of Santarus Inc’s Zegerid powder for oral suspension, Ajanta Pharma said.
This new approval is part of portfolio of products that the company has developed for the US market, it added.
Ajanta Pharma has 26 abbreviated new drug applications (ANDAs) of which it has final approval for 12 ANDAs, tentative approval for 1 ANDA and 13 ANDAs are under review with USFDA, Ajanta Pharma said.
Shares of Ajanta Pharma were trading 2.86 per cent up at Rs. 1,775 on the BSE.
